NICE Approves First NHS-Backed Cream for Vitiligo Treatment

NICE has issued guidance supporting NHS funding of ruxolitinib cream for non-segmental vitiligo, expanding treatment options for eligible patients in England.

On 24 February 2026, NICE recommended ruxolitinib, marketed as Opzelura, for use within the NHS for individuals aged 12 and above with non-segmental vitiligo affecting the face. This decision follows a process involving review and negotiation between NHS England and the manufacturer, Incyte.

Vitiligo is an autoimmune disorder in which the immune system targets melanocytes, the cells responsible for producing skin pigment. Before this recommendation, available treatments included camouflage creams, topical steroids, and phototherapy, each with specific limitations such as the risk of skin thinning, the need for hospital-based procedures, or temporary effectiveness.

NHS England confirmed that nearly 100,000 people aged 12 and over with non-segmental vitiligo will be eligible for ruxolitinib cream. The treatment is intended for those who have not responded to standard steroid creams or for whom such creams are unsuitable, and it is applied twice daily.

What the numbers show

• NICE recommendation was published on 24 February 2026
• More than 80,000 adults and teenagers in England could benefit
• Clinical trials reported at least 75% skin colour return in many patients

Clinical trial results indicated that ruxolitinib cream led to greater facial re-pigmentation compared to placebo. Many participants in these studies achieved at least a 75% restoration of skin colour in affected areas.

Following a rapid assessment and negotiations, NHS England reached an agreement with Incyte, the manufacturer of ruxolitinib cream. This arrangement allowed NICE to proceed with the approval and reimbursement of the treatment for eligible patients through the NHS.

Incyte Biosciences UK confirmed that NICE authorised reimbursement for Opzelura cream at a strength of 15 mg/g for patients meeting the specified criteria. The Vitiligo Society stated that this marks the first time the NHS has recognised and funded a dedicated treatment for repigmentation in vitiligo.

Industry reaction

Incyte Biosciences UK confirmed the NICE decision, stating that Opzelura cream is now reimbursed for eligible NHS patients.

The Vitiligo Society stated that this is the first occasion the NHS has provided funding for a dedicated repigmentation therapy for vitiligo.

* This article is based on publicly available information at the time of writing.